Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

However, the quality of the evidence is poor and insufficient for licensing purposes in many Western countries.

Who Took Part

PubMed indexes the participants as adults.

Participants in both study arms will also receive a behavioural support programme comprising an average of three follow-up telephone calls delivered over an eight-week period by Quitline.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Therapeutic nicotine (patch, non-peptide) was given.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

The primary outcome is continuous abstinence from smoking at one month, defined as not smoking more than five cigarettes since quit date.

Outcome data will also be collected at one week, two months and six months post-quit date.

What Was Measured

The subject headings attached to it are Alkaloids, Azocines, Clinical Protocols, Motivation, Nicotine, Quinolizines and Sample Size.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (BMC public health), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.